Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lot consistency and immunogenicity study of MenACYW in adolescents and adults
2018-001468-48Phase 3
- Sponsor
- Sanofi
- Start
- Jul 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Meningococcal conjugate vaccine quadrivalent in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoint: Geometric mean titer ratios of hSBA antibodies between MenACYW lots.
02
Drugs
Meningococcal conjugate vaccine quadrivalent
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2018-001468-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001468-48.